Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 21Leukemia, Myeloid, Acute 8Hodgkin Disease 8Recurrence 7Neoplasms 7Lymphoma 7Neoplasms, Plasma Cell 5Lymphoma, Large B-Cell, Diffuse 5Leukemia 5Carcinoma, Non-Small-Cell Lung 5Waldenstrom Macroglobulinemia 4Sezary Syndrome 4Prostatic Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Mycosis Fungoides 4Lymphoma, T-Cell, Cutaneous 4Lymphoma, Non-Hodgkin 4Lymphoma, Mantle-Cell 4Lymphoma, Large-Cell, Anaplastic 4Lymphoma, Extranodal NK-T-Cell 4Immunoblastic Lymphadenopathy 4Breast Neoplasms 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Myelodysplastic Syndromes 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Lymphocytic, Chronic, B-Cell 3Burkitt Lymphoma 3Advanced Solid Tumors 3Triple Negative Breast Neoplasms 2

Interventions

Cyclophosphamide 3Vincristine 2Prednisone 2Etoposide 2Doxorubicin 2Brentuximab Vedotin 2romidepsin 1prednylidene 1fludarabine phosphate 1fludarabine 1deltacortene 1Vorinostat 1Salvia hispanica seed extract 1Receptors, Chimeric Antigen 1Peripheral Blood Stem Cell Transplantation 1Panobinostat 1MLN 8237 1Lenalidomide 1Lactones 1Ki-1 Antigen 1Ifosfamide 1Diet, Gluten-Free 1Depsipeptides 1Carboplatin 1Bortezomib 1Automobiles 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Enteropathy-Associated T-Cell Lymphoma × Panobinostat × Clear all
NCT00901147 2014-06-27

Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma

Singapore General Hospital

Phase 2 Completed
25 enrolled
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Extranodal NK-T-Cell, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡